Clinical Trial

Evaluation of the Safety, Tolerability and Pharmacokinetics of HY6725 in Healthy Adult Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn the safety, tolerability and pharmacokinetics of single and multiple doses of HY6725 in healthy adult participants. The main questions it aims to answer are: * How is the safety and tolerability following administration of single and multiple doses of HY6725 in healthy adult participants? * What is the PK character of HY6725 following administration of single and multiple doses of HY6725 in healthy adult participants? Researchers will compare HY6725 to a placebo (a look-alike substance that contains no drug) to see if HY6725 is safe and well tolerated. Participants will take HY6725 or a placebo once or twice in single dose group or multiple dose group. And will be follow-up until Day 150.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-12-01; most recent amendment 2026-03-09.
Status change: Not Yet Recruiting → Recruiting 2026-03-02
Trial Details
NCT Number NCT07262281
Lead Sponsor Newsoara Biopharma Co., Ltd.
Conditions Healthy
Enrollment 74 participants
Start Date 2026-02-06
Primary Completion 2027-03 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-03-11